These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 28736743)

  • 1. Oncolytic Adenovirus-Loaded Menstrual Blood Stem Cells Overcome the Blockade of Viral Activity Exerted by Ovarian Cancer Ascites.
    Alfano AL; Nicola Candia A; Cuneo N; Guttlein LN; Soderini A; Rotondaro C; Sganga L; Podhajcer OL; Lopez MV
    Mol Ther Oncolytics; 2017 Sep; 6():31-44. PubMed ID: 28736743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In Vitro and In Vivo Efficacy of a Stroma-Targeted, Tumor Microenvironment Responsive Oncolytic Adenovirus in Different Preclinical Models of Cancer.
    Alfano A; Cafferata EGA; Gangemi M; Nicola Candia A; Malnero CM; Bermudez I; Lopez MV; Ríos GD; Rotondaro C; Cuneo N; Curiel DT; Podhajcer OL; Lopez MV
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Menstrual Blood-Derived Stem Cells as Delivery Vehicles for Oncolytic Adenovirus Virotherapy for Colorectal Cancer.
    Guo Y; Zhang Z; Xu X; Xu Z; Wang S; Huang D; Li Y; Mou X; Liu F; Xiang C
    Stem Cells Dev; 2019 Jul; 28(13):882-896. PubMed ID: 30991894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced Delivery of Oncolytic Adenovirus by Neural Stem Cells for Treatment of Metastatic Ovarian Cancer.
    Mooney R; Majid AA; Batalla-Covello J; Machado D; Liu X; Gonzaga J; Tirughana R; Hammad M; Lesniak MS; Curiel DT; Aboody KS
    Mol Ther Oncolytics; 2019 Mar; 12():79-92. PubMed ID: 30719498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study of the reparative effects of menstrual-derived stem cells on premature ovarian failure in mice.
    Wang Z; Wang Y; Yang T; Li J; Yang X
    Stem Cell Res Ther; 2017 Jan; 8(1):11. PubMed ID: 28114977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genome-wide DNA methylation and hydroxymethylation analysis reveal human menstrual blood-derived stem cells inhibit hepatocellular carcinoma growth through oncogenic pathway suppression via regulating 5-hmC in enhancer elements.
    Wu Y; Chen X; Zhao Y; Wang Y; Li Y; Xiang C
    Stem Cell Res Ther; 2019 May; 10(1):151. PubMed ID: 31151404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncolytic adenovirus inhibits malignant ascites of advanced ovarian cancer by reprogramming the ascitic immune microenvironment.
    Shi G; Shi P; Yu Y; Xu J; Ma J; Zhang Y; Dong Z; Shen L; Dai L; Cheng L; Cheng P; Deng H
    Mol Ther Oncolytics; 2021 Dec; 23():488-500. PubMed ID: 34901391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defining a murine ovarian cancer model for the evaluation of conditionally-replicative adenovirus (CRAd) virotherapy agents.
    González-Pastor R; Ashshi AM; El-Shemi AG; Dmitriev IP; Kashentseva EA; Lu ZH; Goedegebuure SP; Podhajcer OL; Curiel DT
    J Ovarian Res; 2019 Feb; 12(1):18. PubMed ID: 30767772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model.
    Byrne AT; Ross L; Holash J; Nakanishi M; Hu L; Hofmann JI; Yancopoulos GD; Jaffe RB
    Clin Cancer Res; 2003 Nov; 9(15):5721-8. PubMed ID: 14654557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ovarian cancer-derived ascitic fluids induce a senescence-dependent pro-cancerogenic phenotype in normal peritoneal mesothelial cells.
    Mikuła-Pietrasik J; Uruski P; Matuszkiewicz K; Szubert S; Moszyński R; Szpurek D; Sajdak S; Tykarski A; Książek K
    Cell Oncol (Dordr); 2016 Oct; 39(5):473-481. PubMed ID: 27444787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exosomes derived from human menstrual blood-derived stem cells alleviate fulminant hepatic failure.
    Chen L; Xiang B; Wang X; Xiang C
    Stem Cell Res Ther; 2017 Jan; 8(1):9. PubMed ID: 28115012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of an optimized conditionally replicative adenoviral agent for ovarian cancer.
    Zhu ZB; Lu B; Park M; Makhija SK; Numnum TM; Kendrick JE; Wang M; Tsuruta Y; Fisher P; Alvarez RD; Zhou F; Siegal GP; Wu H; Curiel DT
    Int J Oncol; 2008 Jun; 32(6):1179-88. PubMed ID: 18497979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of ovarian cancer with a novel dual targeted conditionally replicative adenovirus (CRAd).
    Rocconi RP; Zhu ZB; Stoff-Khalili M; Rivera AA; Lu B; Wang M; Alvarez RD; Curiel DT; Makhija SK
    Gynecol Oncol; 2007 Apr; 105(1):113-21. PubMed ID: 17173958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Boosting Replication and Penetration of Oncolytic Adenovirus by Paclitaxel Eradicate Peritoneal Metastasis of Gastric Cancer.
    Ishikawa W; Kikuchi S; Ogawa T; Tabuchi M; Tazawa H; Kuroda S; Noma K; Nishizaki M; Kagawa S; Urata Y; Fujiwara T
    Mol Ther Oncolytics; 2020 Sep; 18():262-271. PubMed ID: 32728614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent Therapeutic Activity Against Peritoneal Dissemination and Malignant Ascites by the Novel Anti-Folate Receptor Alpha Antibody KHK2805.
    Ando M; Nagata K; Nihira K; Suzuki Y; Kanda Y; Adachi M; Kubota T; Kameyama N; Nakano M; Ando H; Yamano K; Ishii T; Nakai R; Nakamura K
    Transl Oncol; 2017 Oct; 10(5):707-718. PubMed ID: 28710915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of chemotherapy resistant ovarian cancer with a MDR1 targeted oncolytic adenovirus.
    Rein DT; Volkmer A; Beyer IM; Curiel DT; Janni W; Dragoi A; Hess AP; Maass N; Baldus SE; Bauerschmitz G; Breidenbach M
    Gynecol Oncol; 2011 Oct; 123(1):138-46. PubMed ID: 21741695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mesenchymal Stem Cells Engineered to Secrete Pigment Epithelium-Derived Factor Inhibit Tumor Metastasis and the Formation of Malignant Ascites in a Murine Colorectal Peritoneal Carcinomatosis Model.
    Yang L; Zhang Y; Cheng L; Yue D; Ma J; Zhao D; Hou X; Xiang R; Cheng P
    Hum Gene Ther; 2016 Mar; 27(3):267-77. PubMed ID: 26756933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An oncolytic virus derived from type 2 herpes simplex virus has potent therapeutic effect against metastatic ovarian cancer.
    Fu X; Tao L; Zhang X
    Cancer Gene Ther; 2007 May; 14(5):480-7. PubMed ID: 17290283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transplantation of Menstrual Blood-Derived Mesenchymal Stem Cells Promotes the Repair of LPS-Induced Acute Lung Injury.
    Xiang B; Chen L; Wang X; Zhao Y; Wang Y; Xiang C
    Int J Mol Sci; 2017 Mar; 18(4):. PubMed ID: 28346367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human Menstrual Blood-Derived Mesenchymal Stem Cells as Potential Cell Carriers for Oncolytic Adenovirus.
    Moreno R; Rojas LA; Villellas FV; Soriano VC; García-Castro J; Fajardo CA; Alemany R
    Stem Cells Int; 2017; 2017():3615729. PubMed ID: 28781596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.